NCT07314788

Brief Summary

This study will characterize the subjective and physiological changes associated with empathy following a fear-inducing virtual reality (VR) experience.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
110

participants targeted

Target at P50-P75 for not_applicable

Timeline
12mo left

Started Apr 2026

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress15%
Apr 2026May 2027

First Submitted

Initial submission to the registry

December 18, 2025

Completed
15 days until next milestone

First Posted

Study publicly available on registry

January 2, 2026

Completed
3 months until next milestone

Study Start

First participant enrolled

April 15, 2026

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2027

Last Updated

April 16, 2026

Status Verified

April 1, 2026

Enrollment Period

1.1 years

First QC Date

December 18, 2025

Last Update Submit

April 15, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • Change in self-reported empathy scores

    Participant will view videos of other individuals undergoing a fear-inducing virtual reality (VR) experience and will self-report level of empathy on a scale 0=not at all to 10=extremely. Average empathy ratings will be compared pre-VR and post-VR.

    Baseline (prior to VR experience) and approximately 5 minutes post-VR experience.

  • Change in heart rate

    Average heart rate (beats/minute) will be collected while watching videos of other individuals undergoing a fear-inducing virtual reality (VR) experience and will be compared pre-VR and post-VR.

    Baseline (prior to VR experience) and approximately 5 minutes post-VR experience.

Secondary Outcomes (1)

  • Change in the correlation between self-reported anxiety scores of self and another

    Baseline (prior to VR experience) and approximately 5 minutes post-VR experience.

Study Arms (2)

Fear-inducing Virtual Reality (VR) experience

EXPERIMENTAL

Participants will complete a single virtual reality (VR) exposure lasting approximately 1-2 minutes, involving a fear-inducing scenario (e.g., walking a plank above a high-rise building or canyon).

Behavioral: Fear-inducing Virtual Reality (VR) experience

Neutral Virtual Reality (VR) experience

ACTIVE COMPARATOR

Participants will complete a single virtual reality (VR) exposure lasting approximately 1-2 minutes, involving a neutral scenario (e.g., walking to the edge of a curb at street level).

Behavioral: Neutral Virtual Reality (VR) experience

Interventions

Participants will complete a single virtual reality (VR) exposure involving a fear-inducing scenario (e.g., walking to the edge of a curb at street level).

Neutral Virtual Reality (VR) experience

Participants will complete a single virtual reality (VR) exposure involving a fear-inducing scenario (e.g., walking a plank above a high-rise building or canyon).

Fear-inducing Virtual Reality (VR) experience

Eligibility Criteria

Age18 Years - 25 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • College-aged adults (18-25 years old)
  • English-speaking
  • Normal or corrected vision.
  • Able to provide consent.

You may not qualify if:

  • Presence of a significant and/or unstable medical illness (e.g., cardiovascular disease, cancer, neurological disorder) or head trauma (e.g., concussion).
  • VR contraindications: epilepsy, migraines, flu, sleep deprivation, etc.
  • More than minimal VR experience assessed via self-report (e.g., How often have you used virtual reality in the past? 0=never, 6=very frequently)
  • Extreme phobia of heights and/or spiders will be assessed using Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) specific phobia subscale.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Miami

Coral Gables, Florida, 33146, United States

Location

Study Officials

  • Jennifer Britton, Ph.D.

    University of Miami

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

December 18, 2025

First Posted

January 2, 2026

Study Start

April 15, 2026

Primary Completion (Estimated)

May 31, 2027

Study Completion (Estimated)

May 31, 2027

Last Updated

April 16, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations